Biopharmaceutics and Pharmacokinetics
Biopharmaceutics and pharmacokinetics together describe how a drug moves into, through, and out of the body, and how that movement determines the concentration available to produce an effect. Biopharmaceutics studies how the physicochemical properties of a drug and its dosage form govern its release and absorption, while pharmacokinetics quantifies the time course of absorption, distribution, metabolism, and elimination — the ADME processes.
Definition
Pharmacokinetics is the study of the time course of drug and metabolite concentrations in the body, encompassing absorption, distribution, metabolism, and excretion; biopharmaceutics is the study of how the formulation and physicochemical properties of a drug product influence its release and the rate and extent of its absorption.
Scope
This area orients the reader to the quantitative study of drug disposition: how a dose becomes a systemic concentration, how that concentration changes over time, and the parameters (clearance, volume of distribution, half-life, bioavailability) used to summarise it. It frames the constituent topics — absorption and permeability, distribution and protein binding, metabolism, elimination, and pharmacokinetic parameters — as a reference map rather than as dosing guidance.
Sub-topics
Core questions
- How does the dosage form and the drug's solubility and permeability determine how much drug reaches the systemic circulation?
- How do absorption, distribution, metabolism, and elimination jointly shape the concentration-time profile?
- Which parameters — clearance, volume of distribution, half-life, bioavailability — summarise drug disposition, and how are they estimated?
- How do physiological and formulation factors create variability in exposure between and within individuals?
Key concepts
- ADME (absorption, distribution, metabolism, excretion)
- Bioavailability and first-pass effect
- Clearance
- Volume of distribution
- Elimination half-life
- Compartmental and physiological modelling
- Linear vs nonlinear (saturable) kinetics
- Concentration-time profile and area under the curve (AUC)
Key theories
- Biopharmaceutics Classification System (BCS)
- A framework that classifies drugs by aqueous solubility and intestinal permeability into four classes, linking in vitro dissolution to in vivo absorption and providing a scientific basis for predicting oral bioavailability and for biowaivers.
- Physiological (clearance) approach to drug disposition
- A view that expresses elimination in terms of organ blood flow, intrinsic clearance, and protein binding rather than as a simple rate constant, allowing the physiological determinants of clearance to be reasoned about explicitly.
Mechanisms
After administration, a drug must be released from its dosage form (a biopharmaceutic step), dissolve, and cross biological membranes to enter the systemic circulation; the fraction that does so, relative to an intravenous dose, defines its bioavailability. Once absorbed, the drug distributes into tissues according to its physicochemical properties and plasma-protein binding, captured by the volume of distribution. Elimination proceeds by metabolism (chiefly hepatic) and excretion (chiefly renal), summarised by clearance — the volume of plasma cleared of drug per unit time. Half-life, a derived parameter, follows from the relationship between volume of distribution and clearance. The physiological approach of Wilkinson and Shand expresses hepatic elimination in terms of blood flow, intrinsic clearance, and binding, and the BCS of Amidon and colleagues links a drug's solubility and permeability to the absorption step.
Clinical relevance
Pharmacokinetic reasoning underpins how exposure to a drug is understood and compared across formulations and populations; it explains why bioavailability, clearance, and half-life matter for the duration and magnitude of drug exposure. This entry is a conceptual reference for those processes and parameters and describes how drug disposition is characterised, not how to select or adjust doses for any individual.
Evidence & guidelines
The field rests on a large body of primary pharmacokinetic studies and on regulatory science: the Biopharmaceutics Classification System informs international guidance on dissolution testing and biowaivers, and standard texts such as Rowland and Tozer and Shargel and Yu codify the parameters and models used throughout drug development and clinical pharmacology.
History
Quantitative pharmacokinetics emerged in the mid-twentieth century from efforts to describe drug concentrations with compartmental models, and matured as the clearance concept gave disposition a physiological footing in the 1970s. Biopharmaceutics developed in parallel as formulation science recognised that the dosage form, not only the molecule, controls absorption; the 1995 Biopharmaceutics Classification System unified solubility, permeability, and dissolution into a predictive framework that reshaped both drug development and regulatory practice.
Key figures
- Gordon L. Amidon
- Malcolm Rowland
- Thomas N. Tozer
- Grant R. Wilkinson
- Leslie Z. Benet
Related topics
Seminal works
- amidon-1995
- wilkinson-shand-1975
- rowland-tozer-2011
Frequently asked questions
- What is the difference between biopharmaceutics and pharmacokinetics?
- Biopharmaceutics studies how a drug's formulation and physicochemical properties affect its release and absorption, whereas pharmacokinetics quantifies the time course of the drug in the body once it is absorbed — the two are complementary parts of understanding drug exposure.
- What do the letters in ADME stand for?
- ADME stands for absorption, distribution, metabolism, and excretion — the four processes that together determine how drug concentrations rise and fall over time.